Zonisamide for Heavy Drinkers With Bipolar Disorder

Bipolar Disorder Clinical Trial

— ZNSBP  

Official title:

Zonisamide for Heavy Drinkers With Bipolar Disorder

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01566370
• Other study ID #: ZNS-BP
• Secondary ID: VACT MIRECCK23AA
• Status: Terminated
• Phase: Phase 2
• First received: December 15, 2011
• Last updated: January 4, 2016
• Start date: May 2012
• Est. completion date: September 2016

Study information

• Verified date: January 2016
• Source: VA Connecticut Healthcare System
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal GovernmentUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double blind, placebo controlled trial of the medication zonisamide for the purpose of reducing heavy drinking and drinking, as well as reducing mood symptoms, in bipolar subjects that drink excessively and heavily.

Hypotheses: (Primary aims); Add-on zonisamide compared to placebo will result in:

1. significant reduction in heavy drinking days, drinks per week and per drinking day, and significantly greater increase in abstinent days, ii) greater rates of abstinence and abstinence to heavy drinking, greater reduction in biomarkers of heavy alcohol use such as gamma-glutamyl transferase (GGT), and greater reduction in alcohol urge or "craving",

2. Significant reduction in prevalent mood symptoms on the BRMS and BRMeS, CARS, HAMD, or no worsening of euthymic mood, and significant improvement on the Clinical Global Impressions Scale-Severity.

3. (Secondary aims) Add-on zonisamide compared to placebo will result in significant reduction in weight (kilograms) and other secondary weight-related metabolic factors such as fasting glucose, lipid profile, and blood pressure.

4. (Secondary aims) Add-on zonisamide compared to placebo will result in improved clinical global impression, overall functioning, quality of life, and reduced medical symptoms.

5.) (Exploratory Aims) To will examine interactions between genotype and medication on treatment response for allelic variation in genetic loci related to the major neurotransmitter and neurophysiologic pathways that are relevant to bipolar disorder, alcoholism, and zonisamide mechanism of action.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: September 2016
• Est. primary completion date: April 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Female/male aged 18-65 years

• Ability to provide informed consent to participate

• Presence of Axis I diagnosis of BD (either type I, Type II, or NOS), in manic, hypomanic, depressive, mixed, or euthymic states plus presence of Axis I diagnosis of a current AUD and/or "at risk" regular heavy drinking (must average >2 heavy drinking days per week) with the goal of reducing or stopping drinking

• treatment with a standard mood stabilizer medication and or other medications with known psychotropic effects on mood state but not alcohol use; Lithium, and/or atypical antipsychotic medications will be the preferred medications,

• Subjects not on any primary acceptable mood stabilizer as described above must be willing to begin treatment with Lithium in open label fashion,

• English speaking, Able to read at the eighth grade or higher level and show no evidence of significant cognitive impairment;

• Women of child-bearing potential (i.e., no hysterectomy, bilateral oophorectomy, or tubal ligation or <2 years postmenopausal), must be non-lactating, practicing a reliable method of birth control, and have a negative serum pregnancy test prior to initiation of treatment;

• Must continue to have at least 2 heavy drinking days per week (averaged per month, with heavy drinking defined as having >4 standard drinks per day for males, and >3 standard drinks per day for females) up to the screening appointment

Exclusion Criteria:

• Presence of another major Axis I disorder such as Schizophrenia or Schizoaffective disorder, Delusional disorder, or other severe psychiatric disorder. A history of suicidal or violent behavior which, in the opinion of the study physician, puts the patient at significant risk of suicide or homicide during the study.

• Past history of drug abuse or dependence will be allowed, but active drug dependence (with the exception of nicotine dependence) in the last 30 days will be disqualifying.

• Serious neurological, or endocrine disorder,

• Evidence of potentially serious or as yet undiagnosed medical problems,

• Neurocognitive cognitive or language limitations, or other incapacity with providing informed consent;

• Known adverse reaction to zonisamide, sulfa-drug allergy, penicillin allergy, other severe adverse drug reaction or allergy, or any serious systemic autoimmune illness,

• Patients currently undergoing ECT treatment.

• Also patients with a history of seizures (other than febrile seizures), renal calculi, or currently taking medications that could either significantly increase the risk of seizures (e.g., tricyclic antidepressant agents, Bupropion, clozaril), or that could potentially theoretically significantly influence drinking behavior such as benzodiazepines, stimulants, opioid painkillers, sedative-hypnotics, etc.).

• Subjects on the following anticonvulsant medications will also be excluded as they may increase the risk of similar side-effects (similar to zonisamide) such as rash, cognitive impairment, or potentially could confound the study of drinking behavior; topiramate, tiagabine, oxcarbazepine, carbamezapine, valproic acid, lamotrigine

• Patients who, on clinical examination by a physician, are deemed to be too severely alcohol dependent to permit them to participate in an outpatient level of care medication trial. We have, over the years, developed methods for reliably and safely assessing patients for alcohol treatment and dual diagnosis studies.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Alcohol Drinking
• Alcohol Use Disorders
• Alcoholic Intoxication
• Bipolar Disorder
• Disease

Intervention

Drug:
• Zonisamide
titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose
• Placebo
placebo

Locations

Country	Name	City	State
United States	VA Connecticut Healthcare System	West Haven	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
VA Connecticut Healthcare System	National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of total Heavy Drinking Days	The percentage of total heavy drinking days compared between groups (zonisamide and placebo) during the time spent on the target dose of the medication (i.e., not including the titration or taper periods), totaled between the time-points of weeks 11 and 14 (4 weeks time frame)	from week 11 through 14 (over 4 weeks)	No
Primary	Change on Hamilton Depression Rating Scale	Change from baseline to endpoint in Hamilton scores compared between medication and placebo, using repeated measures	14 weeks	No
Primary	Change in Clinician Assisted Rating Scale for Mania (CARS-M) Scores	Comparison between groups on change in scores on the CARS-M over 14 weeks from baseline to endpoint, measured weekly and analyzed with repeated measures	14 weeks	No
Secondary	Percentage of Abstinent Days	The difference in total percentage of abstinent compared between groups (zonisamide and placebo) during the time spent on the target dose of the medication (i.e., not including the titration or taper periods), which includes week 11, 12, 13, and 14.	over four weeks, from week 11 through 14	No
Secondary	Change in Alcohol Urge Questionnaire Score	This is the change in AUQ scores (urge to drink) measured weekly compared between groups using repeated measures	from baseline to endpoint, 14 weeks	No
Secondary	Change in Gamma glutamyl transferase (GGT)	Difference between groups on change in levels of GGT over time, measured at baseline, week 5, week 9, week 13, and enpoint, using repeated measures	14 weeks	No
Secondary	Change in Beck Depression Inventory (BDI) Scores	Comparison between groups on change in BDI scores over the 14 weeks of the study, measured weekly, using repeated measures	14 weeks	No
Secondary	Percentage of total drinking days	The percentage of total drinking days compared between groups (zonisamide and placebo) during the time spent on the target dose of the medication (i.e., not including the titration or taper periods), which includes week 11, 12, 13, and 14.	4 weeks	No
Secondary	Change in number of heavy drinking days per week by time	A comparison between medication and placebo on the measure of number heavy drinking days per week over the course of the study (baseline to endpoint) via interaction with time using repeated measures	14 weeks (baseline to endpoint)	No
Secondary	Change in number of drinks per week by time	Comparison between medication and placebo groups on the change in number of drinks per week via interaction with time (from baseline to endpoint) using repeated measures	14 weeks (baseline to endpoint)	No